311 related articles for article (PubMed ID: 18789398)
1. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Travaglini L; Vian L; Billi M; Grignani F; Nervi C
Int J Biochem Cell Biol; 2009 Jan; 41(1):225-34. PubMed ID: 18789398
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells.
Fortunati N; Bertino S; Costantino L; De Bortoli M; Compagnone A; Bandino A; Catalano MG; Boccuzzi G
Mol Cell Endocrinol; 2010 Jan; 314(1):17-22. PubMed ID: 19772891
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
Moggs JG; Murphy TC; Lim FL; Moore DJ; Stuckey R; Antrobus K; Kimber I; Orphanides G
J Mol Endocrinol; 2005 Apr; 34(2):535-51. PubMed ID: 15821115
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.
Davis T; Kennedy C; Chiew YE; Clarke CL; deFazio A
Clin Cancer Res; 2000 Nov; 6(11):4334-42. PubMed ID: 11106251
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
6. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
7. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells.
Abukhdeir AM; Blair BG; Brenner K; Karakas B; Konishi H; Lim J; Sahasranaman V; Huang Y; Keen J; Davidson N; Vitolo MI; Bachman KE; Park BH
Breast Cancer Res Treat; 2006 Sep; 99(1):23-33. PubMed ID: 16541319
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11.
Helguero LA; Faulds MH; Gustafsson JA; Haldosén LA
Oncogene; 2005 Oct; 24(44):6605-16. PubMed ID: 16007178
[TBL] [Abstract][Full Text] [Related]
10. Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines.
Treeck O; Juhasz-Boess I; Lattrich C; Horn F; Goerse R; Ortmann O
Breast Cancer Res Treat; 2008 Aug; 110(3):507-20. PubMed ID: 17876701
[TBL] [Abstract][Full Text] [Related]
11. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Fortunati N; Bertino S; Costantino L; Bosco O; Vercellinatto I; Catalano MG; Boccuzzi G
Cancer Lett; 2008 Feb; 259(2):156-64. PubMed ID: 18006146
[TBL] [Abstract][Full Text] [Related]
12. Eliminating epigenetic barriers induces transient hormone-regulated gene expression in estrogen receptor negative breast cancer cells.
Fleury L; Gerus M; Lavigne AC; Richard-Foy H; Bystricky K
Oncogene; 2008 Jul; 27(29):4075-85. PubMed ID: 18317449
[TBL] [Abstract][Full Text] [Related]
13. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
15. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.
Im JY; Park H; Kang KW; Choi WS; Kim HS
Chem Biol Interact; 2008 Apr; 172(3):235-44. PubMed ID: 18313654
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic information and estrogen receptor alpha expression in breast cancer.
Giacinti L; Claudio PP; Lopez M; Giordano A
Oncologist; 2006 Jan; 11(1):1-8. PubMed ID: 16401708
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Margueron R; Duong V; Castet A; Cavaillès V
Biochem Pharmacol; 2004 Sep; 68(6):1239-46. PubMed ID: 15313422
[TBL] [Abstract][Full Text] [Related]
18. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells.
Lindberg K; Ström A; Lock JG; Gustafsson JA; Haldosén LA; Helguero LA
J Cell Physiol; 2010 Jan; 222(1):156-67. PubMed ID: 19780039
[TBL] [Abstract][Full Text] [Related]
19. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer.
Tabuchi Y; Matsuoka J; Gunduz M; Imada T; Ono R; Ito M; Motoki T; Yamatsuji T; Shirakawa Y; Takaoka M; Haisa M; Tanaka N; Kurebayashi J; Jordan VC; Naomoto Y
Int J Oncol; 2009 Feb; 34(2):313-9. PubMed ID: 19148464
[TBL] [Abstract][Full Text] [Related]
20. Expression of estrogen receptor alpha and progesterone receptor in normal human breast epithelium.
Umekita Y; Souda M; Ohi Y; Rai Y; Sagara Y; Sagara Y; Yoshida H
In Vivo; 2007; 21(3):535-9. PubMed ID: 17591366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
